Clinical Trial Update: A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports completion of Phase 1/2 evaluation of KP-413 for safety, tolerability, and efficacy in atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• KP-413

Snippet

Sponsor: Kaken Pharmaceutical | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED